» Articles » PMID: 35584623

Urolithin A Improves Muscle Strength, Exercise Performance, and Biomarkers of Mitochondrial Health in a Randomized Trial in Middle-aged Adults

Overview
Journal Cell Rep Med
Publisher Cell Press
Date 2022 May 18
PMID 35584623
Authors
Affiliations
Soon will be listed here.
Abstract

Targeting mitophagy to activate the recycling of faulty mitochondria during aging is a strategy to mitigate muscle decline. We present results from a randomized, placebo-controlled trial in middle-aged adults where we administer a postbiotic compound Urolithin A (Mitopure), a known mitophagy activator, at two doses for 4 months (NCT03464500). The data show significant improvements in muscle strength (∼12%) with intake of Urolithin A. We observe clinically meaningful improvements with Urolithin A on aerobic endurance (peak oxygen oxygen consumption [VO]) and physical performance (6 min walk test) but do not notice a significant improvement on peak power output (primary endpoint). Levels of plasma acylcarnitines and C-reactive proteins are significantly lower with Urolithin A, indicating higher mitochondrial efficiency and reduced inflammation. We also examine expression of proteins linked to mitophagy and mitochondrial metabolism in skeletal muscle and find a significant increase with Urolithin A administration. This study highlights the benefit of Urolithin A to improve muscle performance.

Citing Articles

Urolithin A provides cardioprotection and mitochondrial quality enhancement preclinically and improves human cardiovascular health biomarkers.

Liu S, Faitg J, Tissot C, Konstantopoulos D, Laws R, Bourdier G iScience. 2025; 28(2):111814.

PMID: 40034121 PMC: 11875685. DOI: 10.1016/j.isci.2025.111814.


A framework of biomarkers for skeletal muscle aging: a consensus statement by the Aging Biomarker Consortium.

Huang N, Ge M, Liu X, Tian X, Yin P, Bao Z Life Med. 2025; 3(6):lnaf001.

PMID: 40008206 PMC: 11851484. DOI: 10.1093/lifemedi/lnaf001.


Mitophagy is required to protect against excessive skeletal muscle atrophy following hindlimb immobilization.

Rahman F, Graham M, Adam A, Juracic E, Tupling A, Quadrilatero J J Biomed Sci. 2025; 32(1):29.

PMID: 39979946 PMC: 11844018. DOI: 10.1186/s12929-025-01118-w.


The polyphenol metabolite urolithin A suppresses myostatin expression and augments glucose uptake in human skeletal muscle cells.

Wilhelmsen A, Karagounis L, Bennett A, DAmico D, Fouassier A, Jones S Nutr Metab (Lond). 2025; 22(1):12.

PMID: 39962542 PMC: 11834323. DOI: 10.1186/s12986-025-00909-0.


Skeletal Muscle Mitochondrial and Autophagic Dysregulation Are Modifiable in Spinal Muscular Atrophy.

Mikhail A, Ng S, Xhuti D, Lesinski M, Chhor J, Deguise M J Cachexia Sarcopenia Muscle. 2025; 16(1):e13701.

PMID: 39901351 PMC: 11790611. DOI: 10.1002/jcsm.13701.


References
1.
Milburn M, Lawton K . Application of metabolomics to diagnosis of insulin resistance. Annu Rev Med. 2013; 64:291-305. DOI: 10.1146/annurev-med-061511-134747. View

2.
Jing T, Liao J, Shen K, Chen X, Xu Z, Tian W . Protective effect of urolithin a on cisplatin-induced nephrotoxicity in mice via modulation of inflammation and oxidative stress. Food Chem Toxicol. 2019; 129:108-114. DOI: 10.1016/j.fct.2019.04.031. View

3.
Kelstrup C, Bekker-Jensen D, Arrey T, Hogrebe A, Harder A, Olsen J . Performance Evaluation of the Q Exactive HF-X for Shotgun Proteomics. J Proteome Res. 2017; 17(1):727-738. DOI: 10.1021/acs.jproteome.7b00602. View

4.
Tomas-Barberan F, Gonzalez-Sarrias A, Garcia-Villalba R, Nunez-Sanchez M, Selma M, Garcia-Conesa M . Urolithins, the rescue of "old" metabolites to understand a "new" concept: Metabotypes as a nexus among phenolic metabolism, microbiota dysbiosis, and host health status. Mol Nutr Food Res. 2016; 61(1). DOI: 10.1002/mnfr.201500901. View

5.
Tang L, Mo Y, Li Y, Zhong Y, He S, Zhang Y . Urolithin A alleviates myocardial ischemia/reperfusion injury via PI3K/Akt pathway. Biochem Biophys Res Commun. 2017; 486(3):774-780. DOI: 10.1016/j.bbrc.2017.03.119. View